Ascendiant Capital Markets Forecasts Strong Price Appreciation for Atossa Therapeutics (NASDAQ:ATOS) Stock
Atossa Therapeutics (NASDAQ:ATOS – Free Report) had its price objective lifted by Ascendiant Capital Markets from $7.00 to $7.25 in a research report released on Monday,Benzinga reports. They currently have a buy rating on the stock. Separately, HC Wainwright reissued a “buy” rating and issued a $7.00 price objective on shares of Atossa Therapeutics in […]
Atossa Therapeutics (NASDAQ:ATOS – Free Report) had its price objective lifted by Ascendiant Capital Markets from $7.00 to $7.25 in a research report released on Monday,Benzinga reports. They currently have a buy rating on the stock. Separately, HC Wainwright reissued a “buy” rating and issued a $7.00 price objective on shares of Atossa Therapeutics in […]